Abstract
Cilostazol, an antiplatelet drug that also may inhibit smooth muscle proliferation, was given together with aspirin after primary stenting to treat patients with acute myocardial infarction. In a randomized controlled trials of 50 patients, clinical and angiographic outcome at 6 months was significantly improved with cilostazol, depicting a significantly smaller late loss and/or loss index.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Angioplasty, Balloon, Coronary*
-
Aspirin / administration & dosage
-
Aspirin / adverse effects
-
Cilostazol
-
Coronary Angiography / drug effects*
-
Female
-
Fibrinolytic Agents / administration & dosage*
-
Fibrinolytic Agents / adverse effects
-
Humans
-
Male
-
Middle Aged
-
Myocardial Infarction / diagnostic imaging
-
Myocardial Infarction / therapy*
-
Premedication
-
Stents*
-
Tetrazoles / administration & dosage*
-
Tetrazoles / adverse effects
-
Ticlopidine / administration & dosage
-
Ticlopidine / adverse effects
-
Treatment Outcome
Substances
-
Fibrinolytic Agents
-
Tetrazoles
-
Cilostazol
-
Ticlopidine
-
Aspirin